Price (delayed)
$8.2
Market cap
$564.26M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.42
Enterprise value
$501.26M
EYP-1901 is a potential twice-yearly sustained delivery intravitreal anti-VEGF treatment for wet age-related macular degeneration. EYP-1901 leverages a bioerodible formulation of EyePoint's proprietary Durasert® sustained release technology with vorolanib, a
There are no recent dividends present for EYPT.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.